文献速递腹部CT

临床I期胰腺导管腺癌诊断前1年以上CT检查中胰腺异常表现:病例对照研究

CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study.
PubMed 文献 · AJR Am J Roentgenol · 2021-06-23

回顾性纳入103例临床I期胰腺导管腺癌患者与103例对照,分析诊断前至少1年CT上的胰腺局灶异常。诊断前最近一次CT上53.4%患者存在局灶异常(对照20.4%,p<.001),最常见为萎缩(37.9%)、淡薄强化(26.2%)和主胰管改变(13.6%),且异常出现频率随距诊断时间延长而下降。

要点

  • 临床I期胰腺导管腺癌患者诊断前1年以上CT上超过半数可见胰腺局灶异常。
  • 诊断前CT最常见的局灶异常为胰腺萎缩、淡薄强化和主胰管改变。
  • 98.2%患者胰腺导管腺癌部位与诊断前CT局灶异常位置(精确位置或异常上下游边缘)对应。

核心结论

  • 多数临床I期胰腺导管腺癌患者在诊断前至少1年CT上已显示胰腺局灶异常;主胰管改变从出现到确诊持续时间最短,萎缩和淡薄强化病程相对较长。

研究设计与样本

  • 回顾性病例对照研究,纳入103例临床I期胰腺导管腺癌患者(均有诊断前至少1年的CT)和103例无胰腺导管腺癌对照(CT间隔至少10年),分析诊断前CT上胰腺局灶异常(胰腺肿块、主胰管改变、实质萎缩、淡薄实质强化、囊肿、实质钙化)的频率和时间特征。

关键影像表现/征象

  • 诊断前最近一次CT上,胰腺导管腺癌组55/103(53.4%)存在胰腺局灶异常,对照组21/103(20.4%),p<.001。
  • 胰腺导管腺癌组诊断前CT最常见局灶异常为萎缩39/103(37.9%)、淡薄强化17/65(26.2%)和主胰管改变14/103(13.6%),均较对照组更常见(p<.05)。
  • 胰腺导管腺癌组54/55(98.2%)患者的胰腺导管腺癌部位与诊断前CT局灶异常位置(精确位置或异常上下游边缘)对应。
  • 胰腺导管腺癌组诊断前CT局灶异常频率随距确诊时间延长而下降:>1至≤2年64.9%,>2至≤3年49.2%,>3至≤5年41.8%,>5至≤7年29.7%,>7至≤10年18.5%,10年以上0%。
  • 胰腺导管腺癌组从局灶异常首次出现至确诊的平均持续时间:萎缩4.6年,淡薄强化3.3年,主胰管改变1.1年。

临床应用与阅片要点

  • 阅片时注意胰腺实质萎缩、淡薄实质强化和主胰管改变等局灶异常,这些征象可在胰腺导管腺癌确诊前1年以上出现。
  • 发现胰腺局灶异常时,其精确位置或上下游边缘可能是后续胰腺导管腺癌的发生部位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Pancreatic ductal adenocarcinoma (PDAC) is highly lethal, partly because of challenges in early diagnosis. However, the prognosis for earlier stages (carcinoma in situ or category T1a invasive carcinoma) is relatively favorable. OBJECTIVE. The purpose of this study was to investigate findings of an earlier diagnosis of PDAC on CT examinations performed at least 1 year before the diagnosis of clinical stage I PDAC. METHODS. This retrospective study included 103 patients with clinical stage I PDAC and a CT examination performed at least 1 year before the CT examination that detected PDAC, as well as 103 control patients without PDAC on CT examinations separated by at least 10 years. The frequency and temporal characteristics of focal pancreatic abnormalities (pancreatic mass, main pancreatic duct [MPD] change, parenchymal atrophy, faint parenchymal enhancement, cyst, and parenchymal calcification) seen on CT examinations conducted before diagnosis (prediagnostic CT) were determined. RESULTS. A focal pancreatic abnormality was present on the most recent prediagnostic CT examination in 55/103 (53.4%) patients with PDAC versus 21/103 (20.4%) control patients (p < .001). In patients with PDAC, the most common focal abnormalities on prediagnostic CT were atrophy (39/103, 37.9%), faint enhancement (17/65, 26.2%), and MPD change (14/103, 13.6%), which were all more frequent in patients with PDAC than in control patients (p < .05). In 54/55 (98.2%) patients with PDAC, the PDAC corresponded to the site of a focal abnormality (exact location or the abnormality's upstream or downstream edge) on prediagnostic CT. Frequency of focal abnormalities decreased with increasing time before CT that detected PDAC (> 1 to ≤ 2 years before diagnosis, 64.9%; > 2 to ≤ 3 years, 49.2%; > 3 to ≤ 5 years, 41.8%; > 5 to ≤ 7 years, 29.7%; > 7 to ≤ 10 years, 18.5%; more than 10 years, 0%). Mean duration from the finding's initial appearance to diagnosis of PDAC was 4.6 years for atrophy, 3.3 years for faint enhancement, and 1.1 years for MPD change. CONCLUSION. Most patients with clinical stage I PDAC showed focal pancreatic abnormalities on CT performed at least 1 year before diagnosis. Focal MPD change exhibited the shortest duration from its development to subsequent diagnosis, whereas atrophy and faint enhancement exhibited a relatively prolonged course. CLINICAL IMPACT. These findings could facilitate earlier PDAC diagnosis and thus improve prognosis.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Toshima F, Watanabe R, Inoue D, et al. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study. AJR Am J Roentgenol. 2021. PMID: 34161128. doi:10.2214/AJR.21.26014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。